JP2016515621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515621A5 JP2016515621A5 JP2016506360A JP2016506360A JP2016515621A5 JP 2016515621 A5 JP2016515621 A5 JP 2016515621A5 JP 2016506360 A JP2016506360 A JP 2016506360A JP 2016506360 A JP2016506360 A JP 2016506360A JP 2016515621 A5 JP2016515621 A5 JP 2016515621A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lymphoma
- cancer
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 10
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 8
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 5
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 201000007455 central nervous system cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 3
- 208000013706 tumor of meninges Diseases 0.000 claims 3
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 241000195955 Equisetum hyemale Species 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 201000000512 Intraocular Lymphoma Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000000869 occipital lobe Anatomy 0.000 claims 1
- 210000001152 parietal lobe Anatomy 0.000 claims 1
- 210000004560 pineal gland Anatomy 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 201000000513 retina lymphoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000003478 temporal lobe Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807605P | 2013-04-02 | 2013-04-02 | |
| US61/807,605 | 2013-04-02 | ||
| PCT/US2014/032483 WO2014165482A1 (en) | 2013-04-02 | 2014-04-01 | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515621A JP2016515621A (ja) | 2016-05-30 |
| JP2016515621A5 true JP2016515621A5 (enExample) | 2017-05-18 |
| JP6469077B2 JP6469077B2 (ja) | 2019-02-13 |
Family
ID=50588939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506360A Active JP6469077B2 (ja) | 2013-04-02 | 2014-04-01 | ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9839632B2 (enExample) |
| EP (1) | EP2981262A1 (enExample) |
| JP (1) | JP6469077B2 (enExample) |
| KR (1) | KR20150136078A (enExample) |
| CN (1) | CN105246480A (enExample) |
| AU (1) | AU2014248263A1 (enExample) |
| BR (1) | BR112015025252A2 (enExample) |
| CA (1) | CA2907908A1 (enExample) |
| EA (1) | EA201591902A1 (enExample) |
| HK (1) | HK1219896A1 (enExample) |
| MX (1) | MX2015013912A (enExample) |
| PH (1) | PH12015502266A1 (enExample) |
| SG (1) | SG11201507759WA (enExample) |
| WO (1) | WO2014165482A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7143296B2 (ja) | 2016-11-24 | 2022-09-28 | ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 |
| CN107875128A (zh) * | 2017-12-06 | 2018-04-06 | 佛山市弘泰药物研发有限公司 | 一种泊马度胺口崩片及其制备方法 |
| JP7357637B2 (ja) * | 2018-01-02 | 2023-10-06 | セルジーン コーポレイション | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの同位体置換体 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| MX2022004727A (es) | 2019-10-21 | 2022-05-13 | Celgene Corp | Metodos de tratamiento de la leucemia linfocitica cronica con 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)benzil)amino)isoindolina-1,3-diona. |
| KR20220103952A (ko) * | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US20080248046A1 (en) * | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| MXPA02010507A (es) | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| JP4242651B2 (ja) * | 2000-11-30 | 2009-03-25 | ザ チルドレンズ メディカル センター コーポレイション | ４−アミノ−サリドマイドエナンチオマーの合成法 |
| WO2002046373A1 (en) | 2000-12-06 | 2002-06-13 | Hariri Robert J | Method of collecting placental stem cells |
| NZ527849A (en) | 2001-02-14 | 2006-09-29 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20120322779A9 (en) | 2001-04-25 | 2012-12-20 | Rhonda Voskuhl | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2752140A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| KR20060109979A (ko) | 2003-12-02 | 2006-10-23 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| KR101224262B1 (ko) | 2004-03-22 | 2013-01-21 | 셀진 코포레이션 | 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법 |
| CA2588990A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| CA2612612C (en) | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
| EP1928492B1 (en) | 2005-09-01 | 2011-02-23 | Celgene Corporation | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| US20080051431A1 (en) | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
| CN101557806A (zh) | 2006-10-19 | 2009-10-14 | 细胞基因公司 | 使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物 |
| CN101909609A (zh) | 2007-11-08 | 2010-12-08 | 细胞基因公司 | 免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途 |
| US20090148853A1 (en) | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| US20100098657A1 (en) | 2007-12-27 | 2010-04-22 | Schafer Peter H | Method of Treating Cancer with Immunomodulatory Compounds and IgG |
| US20090232796A1 (en) | 2008-02-20 | 2009-09-17 | Corral Laura G | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| DK2391355T3 (en) * | 2009-05-19 | 2017-02-27 | Celgene Corp | FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION |
| HK1214552A1 (zh) | 2012-11-05 | 2016-07-29 | 细胞基因公司 | 在腎損傷的受試者中用泊馬度胺治療癌症 |
-
2014
- 2014-04-01 EA EA201591902A patent/EA201591902A1/ru unknown
- 2014-04-01 US US14/781,898 patent/US9839632B2/en active Active
- 2014-04-01 SG SG11201507759WA patent/SG11201507759WA/en unknown
- 2014-04-01 CA CA2907908A patent/CA2907908A1/en not_active Abandoned
- 2014-04-01 MX MX2015013912A patent/MX2015013912A/es unknown
- 2014-04-01 KR KR1020157027212A patent/KR20150136078A/ko not_active Withdrawn
- 2014-04-01 EP EP14720035.6A patent/EP2981262A1/en not_active Withdrawn
- 2014-04-01 AU AU2014248263A patent/AU2014248263A1/en not_active Abandoned
- 2014-04-01 HK HK16108025.4A patent/HK1219896A1/zh unknown
- 2014-04-01 BR BR112015025252A patent/BR112015025252A2/pt not_active IP Right Cessation
- 2014-04-01 WO PCT/US2014/032483 patent/WO2014165482A1/en not_active Ceased
- 2014-04-01 CN CN201480030076.7A patent/CN105246480A/zh active Pending
- 2014-04-01 JP JP2016506360A patent/JP6469077B2/ja active Active
-
2015
- 2015-09-29 PH PH12015502266A patent/PH12015502266A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515621A5 (enExample) | ||
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| JP2009545600A5 (enExample) | ||
| JP2017149726A5 (enExample) | ||
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| JP2016529285A5 (enExample) | ||
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| JP2018530578A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| CA3120999C (en) | CAPSULE FORMULATIONS | |
| JP2020530467A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| JP2016509030A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| US20210251963A1 (en) | Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1 | |
| JP2020510011A5 (enExample) | ||
| KR20220024463A (ko) | 시뉴클레인병증에 대한 치료 | |
| JP2018522881A5 (enExample) | ||
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| JP2020536068A5 (enExample) | ||
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |